Boston Scientific Corporation
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $2.89B | $1.85B | $1.59B | $698.0M | $1.04B | $-82.0M | $4.70B | $1.67B |
| Depreciation & Amortization | $1.37B | $1.27B | $1.20B | $1.14B | $1.09B | $1.12B | $1.01B | $894.0M |
| Depreciation | $471.0M | $412.0M | $367.0M | $333.0M | $352.0M | $333.0M | $311.0M | $296.0M |
| Amortization | $897.0M | $856.0M | $828.0M | $803.0M | $741.0M | $789.0M | $699.0M | $599.0M |
| Stock-Based Compensation | $299.0M | $266.0M | $233.0M | $220.0M | $194.0M | $170.0M | $157.0M | $140.0M |
| Net Cash from Operating Activities | $4.53B | $3.44B | $2.50B | $1.53B | $1.87B | $1.51B | $1.84B | $310.0M |
| Investing Activities | ||||||||
| Capital Expenditures | $876.0M | $790.0M | $711.0M | $588.0M | $554.0M | $376.0M | $461.0M | $316.0M |
| Business Acquisitions | $1.59B | $4.64B | $1.81B | $1.54B | $2.26B | $3.0M | $4.38B | $1.45B |
| Net Cash from Investing Activities | $-2.64B | $-5.69B | $-2.57B | $-2.01B | $-1.60B | $-411.0M | $-5.04B | $-1.92B |
| Financing Activities | ||||||||
| Dividends Paid | — | $0 | $28.0M | $55.0M | $55.0M | $28.0M | $0 | $0 |
| Stock Repurchases | — | — | — | $0 | $0 | $535.0M | $0 | $0 |
| Net Cash from Financing Activities | $-395.0M | $1.81B | $5.0M | $-548.0M | $-95.0M | $293.0M | $2.97B | $1.43B |
| Net Change in Cash | $1.54B | $-450.0M | $-70.0M | $-1.04B | $173.0M | $1.39B | $-222.0M | $-188.0M |
| Free Cash Flow | $3.66B | $2.65B | $1.79B | $938.0M | $1.32B | $1.13B | $1.38B | $-6.0M |